Key TakeawaysShares in Dexcom plunged in extended trading Thursday after the medical devices company posted second quarter results that came in below Wall Street expectations and slashed its annual revenue forecast.Dexcom shares look set to break down from a symmetrical triangle, a chart pattern that often precedes a trending move in the direction of the breakout.The Dexcom share price could attract buying interest at key chart levels including $70, $52, $37, and $24.On the four occasions the relative stren ...

DexCom, Inc. (NASDAQ:DXCM) Q2 2024 Earnings Conference Call July 25, 2024 4:30 PM ET Corporate Participants Sean Christensen - Vice President of Finance, and Investor Relations Kevin Sayer - Chairman, President, and Chief Executive Officer Jereme Sylvain - Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Jeff Johnson - Baird Magaret Andrew - William Blair Travis Steed - Bank of America Matt Taylor - Jefferies Danielle Antalffy - UBS Joanne Wuensch - ...

DexCom (DXCM) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.34 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10.26%. A quarter ago, it was expected that this medical device company would post earnings of $0.27 per share when it actually produced earnings of $0.32, delivering a surprise of 18.52%.Over the last four quarters, the co ...

Key TakeawaysShares of Dexcom tumbled in extended trading Thursday after the company reported second-quarter earnings that missed estimates and slashed its full-year revenue guidance.The maker of glucose monitors said it now expects organic revenue growth of 11% to 13%, down from its projection in April of 17% to 21%.The second quarter "did not meet our high standards," CEO Kevin Sayer said. Shares of Dexcom (DXCM) tumbled over 40% in extended trading Thursday after the company reported second-quarter earni ...

Table of Contents DEXCOM, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51222 (Exact name of registrant as specified in its charter) Delaware 33-0857544 (State or other jurisdictio ...

Core Insights - Dexcom's shares fell over 34% in after-hours trading following disappointing Q2 revenue and weak guidance [1] - The company reported adjusted earnings per share of 43 cents, exceeding the expected 39 cents, but revenue of $1 billion fell short of the $1.04 billion forecast [1] - Revenue increased by 15% year-over-year from $871.3 million, with net income rising to $143.5 million from $115.9 million [1] Financial Performance - Q2 adjusted earnings per share: 43 cents vs. 39 cents expected [1] - Q2 revenue: $1 billion vs. $1.04 billion expected [1] - Year-over-year revenue growth: 15% from $871.3 million [1] - Net income for Q2: $143.5 million, up from $115.9 million [1] Future Guidance - Q3 revenue expectation: between $975 million to $1 billion [1] - Updated full fiscal year revenue guidance: between $4 billion and $4.05 billion, down from previous guidance of $4.20 billion to $4.35 billion [1] Strategic Initiatives - CEO Kevin Sayer acknowledged that execution did not meet high standards despite advancing key strategic initiatives [2] - The company sees a unique opportunity to serve more customers globally with its differentiated product portfolio [2] - Actions are being taken to improve execution and position the company for long-term growth [2]

Revenue Growth and Financial Performance - Revenue grew 15% year-over-year to $1.004 billion in Q2 2024, with U.S. revenue up 19% and international revenue up 7%[1] - Revenue for the three months ended June 30, 2024, was $1,004.3 million, a 15% year-over-year increase from $871.3 million in 2023[15][16] - U.S. revenue for the three months ended June 30, 2024, was $731.9 million, representing 73% of total revenue and a 19% year-over-year growth[16] - International revenue for the three months ended June 30, 2024, was $272.4 million, a 7% year-over-year increase[16] - Sensor and other revenue for the three months ended June 30, 2024, was $947.0 million, a 22% year-over-year growth and 94% of total revenue[17] - Hardware revenue for the three months ended June 30, 2024, was $57.3 million, a 39% year-over-year decline[17] Operating Income and Profitability - GAAP operating income increased to $158.0 million (15.7% of revenue), up 100 basis points YoY, while Non-GAAP operating income rose to $195.4 million (19.5% of revenue), up 130 basis points YoY[1] - GAAP net income for Q2 2024 was $143.5 million ($0.35 per diluted share), up from $115.9 million ($0.28 per diluted share) in Q2 2023[5] - Non-GAAP gross profit for Q2 2024 was $638.1 million (63.5% of revenue), consistent with the same period in 2023[4] - GAAP net income for the three months ended June 30, 2024, was $143.5 million, compared to $115.9 million in 2023[15] - Non-GAAP net income for the three months ended June 30, 2024, was $174.3 million, compared to $139.4 million in 2023[19] - Adjusted EBITDA for the three months ended June 30, 2024, was $283.9 million, a 22% increase from $232.6 million in 2023[19] - GAAP net income for the three months ended June 30, 2024, was $143.5 million, compared to $115.9 million in the same period in 2023[21] - Non-GAAP net income for the three months ended June 30, 2024, was $174.3 million, compared to $139.4 million in the same period in 2023[21] - GAAP diluted net income per share for the three months ended June 30, 2024, was $0.35, compared to $0.28 in the same period in 2023[21] - Non-GAAP diluted net income per share for the three months ended June 30, 2024, was $0.43, compared to $0.34 in the same period in 2023[21] - Adjusted EBITDA excludes non-cash operating charges for share-based compensation, depreciation, and amortization, as well as non-operating items such as interest income, interest expense, and income tax expense or benefit[28] Product Launches and Market Expansion - The company launched Direct-to-Watch in the U.S. and international markets, enabling G7 customers to use Apple Watch as their primary glucose display[2] - Dexcom secured coverage for Dexcom ONE in France for type 2 diabetes patients using basal insulin, expanding reimbursed access to real-time CGM[2] - Dexcom advanced pump connectivity by integrating G7 with Insulet's Omnipod 5 and Tandem's Mobi insulin pump with Control-IQ technology[2] Financial Guidance and Share Repurchase - Dexcom updated 2024 annual revenue guidance to $4.00 - 4.05 billion, representing 11 - 13% organic growth, and expects Q3 2024 revenue of $975 million to $1.00 billion[3] - The company announced a $750 million share repurchase program alongside Q2 2024 results[3] Cash Position and Expenses - Dexcom held $3.12 billion in cash, cash equivalents, and marketable securities as of June 30, 2024, with an undrawn revolving credit facility[6] - Research and development expenses for the three months ended June 30, 2024, were $136.0 million, a 14% increase from $119.3 million in 2023[15] - Selling, general, and administrative expenses for the three months ended June 30, 2024, were $332.7 million, an 11% increase from $299.0 million in 2023[15] - Business transition and related costs for the three months ended June 30, 2024, were primarily related to workforce reduction costs and rent for vacated office space in San Diego, California[21] - Intellectual property litigation costs for the three months ended June 30, 2024, were $0.05 per share, primarily related to Dexcom's patent infringement litigation against Abbott Diabetes Care, Inc.[21] - Tax adjustments for the three months ended June 30, 2024, were primarily related to the tax effect of non-GAAP adjustments and excess tax benefits from share-based compensation for employees[22] Share and Earnings Metrics - GAAP diluted weighted-average shares outstanding for the three months ended June 30, 2024, were 416.8 million, compared to 431.5 million in the same period in 2023[21] - Non-GAAP diluted weighted-average shares outstanding for the three months ended June 30, 2024, were 409.1 million, compared to 407.8 million in the same period in 2023[21]

DexCom, Inc. (DXCM) is scheduled to release second-quarter 2024 results on Jul 25, after the closing bell. In the last reported quarter, the company’s earnings beat estimates by 18.52%.The bottom line also outpaced the consensus mark in each of the trailing four quarters, delivering an average surprise of 34.10%.Q2 EstimatesCurrently, the Zacks Consensus Estimate for revenues is pegged at $1.04 billion, indicating growth of 19% from the year-ago quarter’s reported figure. The consensus mark for earnings is ...

For Immediate ReleasesChicago, IL – July 16, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: DexCom Inc. (DXCM) , Hologic Inc. (HOLX) , Alcon Inc. (ALC) , Intuitive Surgical Inc. (ISRG) and Thermo Fisher Scientific Inc. (TMO) .Here are highlights from Tuesday’s Analyst Blog:Buy 5 Medical Devices Stocks to Enhance ...

Beaten-down stocks can sometimes present an opportunity.Healthcare stocks may not be the most exciting investments for some, but overlooking these businesses could mean you pass up great companies. These are the businesses that provide essential products and services in a wide range of market environments and economic landscapes.While not all healthcare stocks are created equal, finding intriguing businesses to put cash into and adding those to a well-diversified basket of investments can magnify your retur ...